ClinicalTrials.gg
CompletedNCT05959096Updated Oct 1, 2024

A Study of LY3437943 in Healthy Participants With a High Body Mass Index

A Phase 1 interventional study of LY3437943 and LY3437943 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study is conducted in two parts (Part A and B). The main purpose of this study is to look at the amount of the LY3437943 that gets into the blood stream and how long it takes the body to get rid of it when given subcutaneously (SC, under the skin) in the upper arm and thigh compared to the abdomen in healthy participants with high body mass index (BMI) in Part A. In Part B, the participants receive LY3437943 intravenously (IV, through a vein) where the safety and tolerability of LY3437943 are evaluated and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 157 days and 99 days for Part A and Part B, respectively.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures
  • (BMI) between 27.0 and 45.0 kilograms per meter squared (kg/m²), inclusive
  • Are agreeable to receiving study treatment by injections under the skin or through a vein.

Exclusion criteria

Exclusion Criteria:

  • Have a history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form)
  • Have a significant history of, or presence of, any of the following disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Have known allergies to LY3437943, related compounds, or any components of the formulation
  • Smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e cigarettes (nicotine and non nicotine) per day.
  • Is a known user of drugs of abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    LY3437943 (Part A)

    LY3437943 administered subcutaneously (SC) in either thigh, upper arm, or abdomen

    Drug: LY3437943

  • Experimental
    LY3437943 (Part B)

    LY3437943 administered intravenously (IV)

    Drug: LY3437943

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943

    Part A: PK: AUC(0-∞) of LY3437943

    Time frame: Predose on Day 1 up to 43 days postdose (Part A)

  2. Part A: PK: Maximum Concentration (Cmax) of LY3437943

    Part A: PK: Cmax of LY3437943

    Time frame: Predose on Day 1 up to 43 days postdose (Part A)

Secondary outcomes

  1. Part B: PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943

    Part B: PK: AUC(0-∞) of LY3437943

    Time frame: Predose on Day 1 up to 71 days postdose (Part B)

  2. Part B: PK: Maximum Concentration (Cmax) of LY3437943

    Part B: PK: Cmax of LY3437943

    Time frame: Predose on Day 1 up to 71 days postdose (Part B)

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Jul 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 25, 2023
StartActual
Jul 18, 2023
Primary completionActual
Jul 25, 2024
CompletionActual
Jul 25, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05959096
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Jul 18, 2023
Primary completion
Jul 25, 2024
Completion
Jul 25, 2024
Last update
Oct 1, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion